1. Systemic Inflammation, the Peripheral Blood Transcriptome, and Primary Melanoma.
- Author
-
Randerson-Moor J, Davies J, Harland M, Nsengimana J, Bigirumurame T, Walker C, Laye J, Appleton ES, Ball G, Cook GP, Bishop DT, Salmond RJ, and Newton-Bishop J
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Prognosis, Gene Expression Profiling, B7-H1 Antigen blood, B7-H1 Antigen genetics, B7-H1 Antigen metabolism, Fibrinogen analysis, Fibrinogen metabolism, C-Reactive Protein analysis, Gene Expression Regulation, Neoplastic, Signal Transduction, Biomarkers, Tumor blood, Biomarkers, Tumor genetics, Adult, Melanoma blood, Melanoma genetics, Melanoma mortality, Melanoma immunology, Melanoma pathology, Skin Neoplasms blood, Skin Neoplasms genetics, Skin Neoplasms mortality, Skin Neoplasms pathology, Skin Neoplasms immunology, Transcriptome, Inflammation blood, Lymphocytes, Tumor-Infiltrating immunology
- Abstract
Peripheral blood transcriptomes from 383 patients with newly diagnosed melanoma were subjected to differential gene expression analysis. The hypotheses were that impaired systemic immunity is associated with poorer prognosis (thicker tumors and fewer tumor-infiltrating lymphocytes) and evidence of systemic inflammation (high-sensitivity CRP and fibrinogen levels). Higher fibrinogen levels were associated with thicker primary tumors. In single-gene analysis, high-sensitivity CRP levels were significantly associated with higher blood CD274 expression (coding for PD-L1), but each was independently prognostic, with high-sensitivity CRP associated with increased mortality and higher CD274 protective, independent of age. Pathway analysis identified downregulation of immune cell signaling pathways in the blood of people with thicker tumors and notable upregulation of signal transducer and activator of transcription 1 gene STAT1 in people with brisk tumor-infiltrating lymphocytes. Transcriptomic data provided evidence for increased NF-kB signaling with higher inflammatory markers but with reduction in expression of HLA class II molecules and higher CD274, suggesting that aberrant systemic inflammation is a significant mediator of reduced immune function in melanoma. In summary, transcriptomic data revealed evidence of reduced immune function in patients with thicker tumors and fewer tumor-infiltrating lymphocytes at diagnosis. Inflammatory markers were associated with thicker primaries and independently with death from melanoma, suggesting that systemic inflammation contributes to that reduced immune function., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF